The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies
Diabetes is a leading cause of cardiovascular disease and its associated morbidity. While the medical community has had access to numerous glucose lowering therapies over the last decades, it was not until recently that newer agents demonstrated improvement in cardiovascular outcomes. In particular,...
Main Authors: | Devinder S. Dhindsa, Pratik B. Sandesara, Michael D. Shapiro |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-11-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcvm.2018.00160/full |
Similar Items
-
SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins
by: Awadhesh K Singh, et al.
Published: (2019-01-01) -
Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials
by: Lisa Ludwig, et al.
Published: (2020-05-01) -
Diabetes: how to manage cardiovascular risk in secondary prevention patients
by: Sarah L Anderson, et al.
Published: (2022-06-01) -
Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors
by: Cosmin Mihai Vesa, et al.
Published: (2020-05-01) -
Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
by: Stefan D. Anker
Published: (2019-12-01)